Disposable oxygen masks offers a medium to transfer breathing oxygen gas from a storage tank to the lungs. They feature a soft, air-filled cuff to allow a close fit to the patient’s face with an easy grip and a dome with thumb rest, supplied with hook ring. Cushion and mask dome are made up of PVC (Polyvinyl chloride).

Disposable oxygen mask are wore on the face to protect nose & mouth from harmful gases and viruses in the environment that tend to cause infection. In healthcare sector, researchers and physicians usually wear disposable oxygen masks for safety from airborne infections.

Click To Continue Reading on Disposable Oxygen Masks Market

Moreover, disposable face masks are also used by patients suffering from diseases such as chronic obstructive pulmonary disease (COPD), asthma, and others. On the basis of product, disposable oxygen mask are available in the market as pediatric disposable oxygen masks and adult disposable oxygen masks.

For instance, according to the World Health Organization Forum of International Respiratory Societies 2017 report, around 65 million people suffer from COPD (chronic obstructive pulmonary disease) and 3 million die each year from COPD, making it the third major cause of death around the globe.Same report also revealed that around 334 million people suffer from asthma, the most common chronic disease in children affecting 14% of the children, globally. Lung cancer was the cause of death of 1.6 million people each year and pneumonia affects millions of people, annually which is the leading cause of death among the children below 5 years.

Moreover, increasing urbanization and industrialization is leading to poor air quality, which is playing vital factor in rising respiratory diseases and. For instance, according to the World Health Organization 2018 report, 4.2 million deaths every year are caused due to exposure to outdoor air pollution. Also, outdoor air pollution in both rural areas and cities was estimated to cause 4.2 million premature deaths worldwide in 2016. Owing to these factors, physicians advise patients for oxygen therapy using oxygen masks, which is propelling the global disposable oxygen market growth. However, availability of alternative products in the market such as nasal cannula are expected to hinder growth of disposable oxygen masks market size.

Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, and belongs to calcitonin (CT) superfamily of peptides. Procalcitonin is a 116 amino acid peptide that has an estimated molecular weight of 14.5 kDa. It can be segregated into three parts, namely immature calcitonin, calcitonin carboxyl-terminus peptide-1, and amino terminus of the PCT region. Procalcitonin was first classified by Bernard Roos and Leonard J. Deftos in the early 1970s. Procalcitonin is produced by C cells of the thyroid and by endocrine cells of the lung. In human body, level of unprocessed procalcitonin rises extensively after shock, injury or bacterial infection, which increases the production of procalcitonin in the body.

Click To Continue Reading on Procalcitonin Antibody Market

This might lead to organ dysfunction and call for immediate treatment of the patient. The level of procalcitonin in the body can be diagnosed with wet lab analysis using procalcitonin antibody. On the basis of antibody type, the procalcitonin antibody market is segmented into polyclonal procalcitonin antibody and monoclonal procalcitonin antibody. For instance, according to the World Health Organization (WHO) fact sheet of 2018, cancer was responsible for 8.8 million deaths in 2015 globally. Moreover, according to the World Health Organization report of 2017, around 1.0 million deaths occurred due to HIV related illnesses worldwide. Furthermore, WHO 2017, fact sheet revealed that 71 million people were having chronic hepatitis C infection. Approximately 399,000 people die each year from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma.

These incidences have led to the adoption of new techniques and procedures by research institutes and hospitals for quick diagnosis of the diseases, so that it can be treated within the earliest time frame. Moreover, increasing funding for research and development by commercial market players and government agencies for the development of efficient, safer, and innovative products for the treatment of diseases such as cancer is fueling growth of the procalcitonin antibody market. For instance, in 2018, the U.S government approved US$ 3 billion funds for the National Institutes of Health research and development activities.

Asia Pacific is expected to exhibit significant growth in the procalcitonin antibody market, followed by Europe, owing to increasing healthcare researches and rising geriatric population vulnerable to sepsis disease. According to the Center for Strategic and International Studies, in 2015, 9.5% of the population in China was 65 years or older and as per the United Nations, it is projected to reach to 27.5% by 2050.

Peptide cancer vaccines aids to elicit and expand tumor-specific T-cells capable of controlling or eradicating tumor. This vaccine consists of one or more short or long amino acid sequences as tumor antigens, combined with vaccine adjuvant. In the recent past, results of clinical trials performed using peptide cancer vaccine had exhibited negative outcomes. So, researchers in the peptide vaccine have considered this as outdated therapy and declared it as no longer viable for cancer treatment. However, increasing progress in understanding critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has led to re-emergence of this approach for treating malignant disorders.

Click To Continue Reading on Peptide Cancer Vaccine Market

North America market accounted for the largest share in the global peptide cancer vaccine market, followed by Europe market in 2016.

Furthermore, advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, easy to prepare, and its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to foster growth of the peptide cancer vaccine market in the near future. Therefore, owing to these advantages, manufacturers are focusing on research, to develop peptide cancer vaccines. For instance, in April 2018, Boston Biomedical, Inc. involved in next generation cancer therapeutics, initiated dosing of the first patient in each of two clinical studies to evaluate the results of its affectability by using DSP-7888, an investigational cancer peptide vaccine.

According to a National Cancer Institute, 2016, in the U.S., it was estimated that 16.8 million new cases of cancer were diagnosed with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024. Furthermore, the World Health Organization (WHO) reported around 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012. Among these, the common cases pertained to lung, colorectal, prostate, cervical, and breast cancer, which significantly has increased demand for peptide vaccines, in turn aiding in growth of the global peptide cancer vaccine market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1634

Key Vendors:

TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs.

Skin and Soft Tissue Infections (SSTIs) are one of the reason for high rate of morbidity and mortality. Even, in the cases of successful surgeries, affected subcutaneous tissue, fascia, or muscle; remains a delay in the healing process and can lead to life-threatening conditions. This cases are propelling demand for more effective treatments to deal with such pathological situations. Recently, wound dressings loaded with antimicrobial agents has emerged as potential option to reduce wound bacterial colonization and infection to improve the healing process.

Click To Continue Reading @ Antimicrobial Wound Dressing Market

Antimicrobial wound dressing contains drugs such as antimicrobial agents, biologics such as growth factors, or they are composed of materials derived from animal sources. These dressings prevent bacterial penetration into the wound and avoid growth of microorganisms. The commonly encountered antiseptic agents in the antimicrobial dressings are silver, iodine, chlorhexidine, Polyhexamethylbiguanide (PHMB), alginate, and hydrocolloids. Conventional wound dressings take longer time for wound healing as compared to advanced wound dressing products such as antimicrobial and anti-infective wound dressings, which are widely used in post-operation to prevent risk of any Hospital Acquired Infections (HAIs). Antimicrobial wound dressings are rapidly replacing conventional wound dressings due to their high functional efficiency and effectiveness.

Increasing incidence of burns, trauma wounds and injuries, and diabetic ulcers are expected to drive growth of the global antimicrobial wound dressings market over the forecast period. For instance, in January 2017, according to the World Health Organization (WHO) data published in African Journal of Emergency Medicines, burn cases accounted for around 18 million disability cases and more than 2,50,000 deaths annually, out of which over 90% deaths were reported in low- and middle-income economies. The U.S. fire department responded to around 1.3 million fire incidences in 2016, out of which 3,280 civilian deaths and 15,700 civilian injuries were reported by National Fire Protection Association (NFPA).